Leverage China’s development infrastructure to accelerate toward
value inflection.

Riverbird Partners works with biotechnology companies from preclinical proof of concept through initial human proof of concept.

Whether designing the right China operating model, accessing local development partners (CDMOs, CROs, hospitals and investigators), selecting the optimal regulatory pathway (IIT or IND), or integrating China into global development (Australia, USA), we provide on-the-ground expertise and hands-on execution.

Current clients span cell and gene therapy, rare disease, ophthalmology, immunology, nephrology, and CNS.